The accelerating antibiotics crisis requires decisive action. Antibiotics frequently fail and destroy our natural microbiomes. Phages and endolysins work where antibiotics fail and protect our beneficial bacteria. They are our best bet to defuse this existential crisis for modern medicine.
Our lead program PM-477:
Bacterial vaginosis (BV)
Recurrent bacterial vaginosis affects 100 million women across the globe. Today’s therapy relies on long-term suppressive antibiotics that fail to provide a cure. Our engineered lysin works where antibiotics fail and is precise, making it a highly innovative solution.
PhagoMed is member of
PhagoMed is supported by